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Fool’s gold? Why blinded trials are not always best
Blinding is intended to reduce bias but can make studies unnecessarily complex or lead to results
that no longer address the clinical question, argue Rohan Anand and colleagues
Rohan Anand, doctoral research student 1, John Norrie,  professor 2, Judy M Bradley, professor 1,
Danny F McAuley, clinical professor 1, Mike Clarke, professor 3
1Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry, and Biomedical Sciences, Queen’s University Belfast, Belfast,
UK; 2Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK; 3Northern Ireland Clinical Trials Unit
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The essence of blinding is withholding information about
treatment assignment from people involved in the trial. Trials
in which patients, clinicians, and researchers are blinded to the
allocated intervention are usually regarded as the gold standard
of clinical research and evidence.1 2 However, blinding’s
illustrious reputation brings with it the danger that it is regarded
as essential for a trial to be “good,” especially if users place an
uncritical reliance on hierarchies of evidence in which blinded
evaluations are near the top.3 Given that the number of new
trials is increasing every year, with 25 000 registered since the
start of 2019, we are concerned that a substantial amount of
time, energy, and funding may be going into considering and
implementing blinding without a sound rationale for it.4
Past, present, and future trials contain vast amounts of important
data. If trials without blinding are inappropriately judged to be
of lower quality than blinded trials then we may not be making
best use of their data to improve healthcare, while blinded trials
may be producing results that are more difficult to interpret than
they need be. In this article, we seek to stimulate debate by
challenging some of the prevailing beliefs on the benefits of
blinding.
Purpose of blinding
The first recorded instance of blinding is from Paris in 1784.5
This was a study into an unknown, mystical force called
mesmerism and the claims that patients could be healed simply
by encountering a “mesmeriser” or an object that had been
mesmerised. People believed to have been mesmerised would
sometimes show hysterical behaviour, but the French Academy
of Sciences was sceptical. It assembled a distinguished scientific
team, including Antoine Lavoisier and Benjamin Franklin, to
conduct experiments to test mesmerism. The participants were
blinded to which objects were mesmerised or whether a
mesmeriser was behind a curtain and then observed for their
reactions. When they were blinded, mesmerism lost its power,
and the study instead established the power of blinding.
Blinding is used in trials to reduce bias by ensuring that
knowledge of which intervention a given trial participant
received does not influence the judgments of trial participants
or investigators. This allows the identification of the “true effect”
of the new intervention, as distinct from any effect arising
simply from the participant’s knowledge or expectation of
receiving an intervention. In placebo controlled trials, any
placebo effect of the new treatment would be discounted when
comparing the intervention and control group to determine the
effect of the active properties.
Blinding is also used to reduce bias in which the measured effect
is not the true effect.6 Blinding aims to minimise response and
observer bias. Response bias occurs when participants respond
inaccurately, either intentionally or unintentionally. Observer
bias occurs when researchers assessing the effects of the
interventions have presumptions about them and so may
inaccurately measure outcomes, leading to different effect
estimates. Blinding also aims to minimise co-intervention bias,
in which non-trial interventions may be taken differently by the
groups being compared if participants know what they have
been allocated.
Evidence on the ability of blinding to minimise the “placebo
effect” (which can occur regardless of whether an actual placebo
is used) and reduce bias comes from comparisons between
selected trials7 and from systematic reviews of methodology
research,8-12 with lack of blinding leading to an exaggerated
treatment effect of up to 68%. However, there are several
negative consequences that can arise from blinding.
Negative aspects of blinding
The substantial challenges of recruitment and retention in
clinical trials have been highlighted as priorities for research.13 14
Poor recruitment leads to prolonged study times and
underpowered results. These challenges are made worse by
blinding, especially in trials using a placebo control. Trials with
Correspondence to: M Clarke m.clarke@qub.ac.uk
For personal use only: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2020;368:l6228 doi: 10.1136/bmj.l6228 (Published 21 January 2020) Page 1 of 5
Analysis
ANALYSIS
 o
n
 10 M
arch 2020 at University of Edinburgh. Protected by copyright.
http://www.bmj.com/
BM
J: first published as 10.1136/bmj.l6228 on 21 January 2020. Downloaded from 
nested components that were blinded and unblinded found that
blinded designs discouraged people from participating.15-17 Key
reasons given by patients for not wanting to enrol in these trials
were that they wanted a named medication or wanted to know
what was in the tablets. This suggests that achieving blinding
and using a non-active comparator discourages people from
joining a trial. In another study about 25% of patients expressed
concerns about receiving placebos.18
Successful retention of patients is equally important,19 and the
use of a placebo might be damaging if patients who suspect that
they have been allocated to receive it withdraw from the study.
A meta-analysis investigating retention in trials of antipsychotic
interventions concluded that a placebo controlled design
significantly increased dropout.20 Patient preference or resentful
demoralisation can be a problem if patients in a placebo group
lose motivation when they suspect or discover they are not
receiving an active treatment. This could result in bias from
differential loss to follow-up between groups.21 Patients may
feel frustrated because they believe they are receiving inadequate
treatment and so exaggerate negative answers on questionnaires
or even withdraw from the trial.22
The production and packaging of interventions in ways that will
ensure their identity is blinded to participants, including use of
placebo controls, can also cause difficulties. Not only do control
interventions need to look identical to the intervention, any
characteristic taste, texture, smell, colour, or viscosity of the
intervention needs to be matched as well, which can be
expensive.23 Money spent on blinding has opportunity costs if
it reduces funding to optimise other features that would have
more influence on the trial’s robustness such as the training of
trial staff, boosting the sample size, and comprehensively
measuring outcomes.24 Even if the blinded control is designed
to be physically identical to the intervention, any signature side
effects associated with the intervention(s) may lead to
unblinding.25 Examples come from the IMOP trial of isosorbide
mononitrate for cervical ripening26 and the IMAGES trial of
magnesium for acute stroke,27 both of which had high rates of
specific side effects in the intervention arms; even though no
formal unblinding of researchers and patients occurred, those
involved in such trials may have had a good idea about the
groups that patients were in.
In addition to this passive association, others might actively
look for signs that they believe to be linked to the interventions.
The online community group PatientsLikeMe was set up to
enable people to share information on their illnesses. Members
who were enrolled in blinded clinical trials shared their
outcomes, including side effects, on online platforms outside
of the official protocol or any trial regulations, even before the
trial’s completion.28 Their aim was to help each other deduce
their allocated intervention, showing their frustration in the
blinded approach. This highlights that maintaining blinding may
be increasingly difficult in the age of social media and online
networks.29 Researchers have also been found to break blinding
by comparing pills and searching through the restricted notes
of patients.30Box 1 describes other problems that can arise from
blinding.
Box 1: Problems associated with blinding
Emergency unblinding
If an individual’s allocation has to be unblinded for clinical reasons, there is
the potential that this can cascade and unblind others in the trial. A simple
example would be an adverse event needing treatment that is reported by
blinded trial staff, who then code break to identify which intervention the patient
received. Although the trial staff are officially unblinded to only this single case,
they might now associate this event or related symptoms with the specific
intervention. Even worse, if all the interventions had been coded in the same
way (such as “drug A” and “drug B”) those who unblind themselves to one
patient, effectively unblind themselves to all patients. Even in the absence of
such coding, unblinding of patients in a trial using blocked randomisation might
reveal the allocations of patients from the same block or strata.31
Testing for blinding
Testing for the success of blinding in trials has been reported in about 2% of
trials,32 usually by asking those blinded to guess treatment allocation.33-36 In
theory, any significant difference over chance suggests that blinding was
compromised. However, measuring blinding is highly challenging. Asking
people to say which treatment was allocated after outcomes have been
accumulated makes them likely to base their answer on assumptions related
to the effects of the intervention. This was observed in a 2x2 factorial trial of
aspirin and sulfinpyrazone for stroke prevention in which blinded clinicians
were asked to guess treatment groups and did significantly worse than
chance.37 Their guesses seemed to be influenced by their prior assumptions
that sulfinpyrazone was more effective than aspirin and that patients who did
well must have been on sulfinpyrazone, when in fact the trial showed the
opposite.38 This essentially confounds testing for the success of blinding with
expectations about treatment efficacy.
Blinding and risks to patient safety
When blinding might compromise patient safety, it is paramount
to consider whether it is necessary. For example, a placebo
controlled trial of fibrinogen for postpartum haemorrhage
required a moratorium on the use of any new treatments for 15
minutes after the randomly allocated treatment was given, with
the sole purpose of maintaining the blind, potentially creating
an unacceptable risk for the women.39 Similarly, adjusting doses
creates problems in blinded trials and in such situations, using
a fixed dose of a drug with a narrow and volatile therapeutic
range could compromise patient safety. Clinical trials with
anticoagulants40 and antipsychotics have been historically
difficult to blind because of the need for dose adjustments.25
Use of a placebo or other sham therapy might lead to adverse
effects that would not have happened if an open control group
had been used. These could be direct harms from the procedures
intended to ensure blinding, such as infection from piercing the
skin to give a placebo injection or muscular problems from
sham physiotherapy.
In considering these concerns about patient safety, Franklin G
Miller outlined key questions that might help when deciding
whether to use placebos in surgical trials.41 42 It seems reasonable
to apply a similar but expanded set of questions, as listed in box
2, when considering using blinding in all clinical trials. These
questions are context dependent and would be determined by
those designing the trial; if the disadvantages outweigh the
benefits in one of the questions then a blinded trial might not
be appropriate.
Box 2: Questions to consider before using blinding
• Is blinding needed for a scientifically sound result? (Will the intervention
have a placebo effect which needs to be separated from its true effect?)
• How likely is it that patients or clinicians will behave differently if they
know the intervention and would this change in behaviour bias the
results?
• Are the potential harms to patients of using blinding excessive?
• Does the anticipated social value of the study results justify any potential
harms of blinding?
• Does the financial cost of blinding compromise spending on other
methodological aspects of trial integrity?
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Pragmatism and what happens in the real
world
At its simplest, a randomised trial is a comparative effectiveness
study that aims to obtain as unbiased an estimate as possible of
the difference in the outcomes for patients in the treatment group
compared with those in the control group. Beyond this, the
ultimate aim is to generate evidence that can be used to make
assumptions about what will happen to future patients who
receive the treatment after the trial. Blinding might help to
reduce bias but hamper the evidence generated. Minimising
biases with blinding might weaken the ability to predict the
future accurately, because blinding is unlikely to be used in
routine practice. There is a continuum from explanatory to
pragmatic trials, and blinding influences where a trial is on this
continuum.43
Some of the types of blinding that would be contemplated only
in a research setting are inconsistent with the desire for
pragmatism in large, phase III pragmatic effectiveness trials.
Pragmatic trials strive to generate situations that are as close as
possible to routine practice, when patients and clinicians will
not be blinded to the intervention. Outside trial settings the
intervention is known and this will have a legitimate effect on
behaviour, including use of co-interventions, concerns about
side effects, and decisions about continuing or stopping the
therapy. Some interventions will be marketed for
over-the-counter and prescription use, and both patients and
clinicians will be susceptible to brand psychology, meaning
choices will be determined by facets surrounding brand loyalty.44
Clinicians might pay particular attention to assessing patients
for side effects and act if they observe them. Both patients and
clinicians might choose to continue with a therapy they believe
to be active and beneficial and stop taking therapies they believe
to have completed their action, or switch from those that do not
seem to be working. Box 3 gives some hypothetical examples.
Box 3: Examples of clinical trial research questions where
blinding and placebos would damage pragmatism
Does a cream reduce facial acne?
The uncertainty faced by someone looking at the array of acne creams in a
pharmacy is probably not, “Should I use one of these creams or their base
material?” but, “Which one of these creams should I use?” A blinded trial of
two creams to see which would cause a greater reduction in acne, with
independent blinded outcome assessment, would help determine whether the
ingredients have different levels of activity but would not account for what
happens in the real world. Patients’ and clinicians’ perception of how the
creams are branded and marketed affects their behaviour. The influences
related to psychological attachment to a brand, combined with the patient’s
assessment of their acne, could produce different results from those seen in
the blinded trial.
Does cognitive behaviour therapy delivered by a highly skilled
and experienced therapist improve the quit rates of smokers?
When the effects of personally delivered interventions such as psychotherapy,
teaching, and surgery are assessed, we might wish to compare whether there
are differences between those delivered by practitioners with high levels of
training or experience and those delivered by relative novices. This might
have important implications for the costs of the therapy or for the rate at which
patients can receive it.
A blinded trial in which the patient is not informed of the practitioner’s skill and
experience would remove the effect of this knowledge, but in normal practice
they will be aware of this information and it may even influence their decision
to seek out a particular practitioner. Having access to the information might
bias the patient by having a positive effect of helping them to benefit from the
therapy, or, conversely, it might have a negative effect by raising their
expectations of benefit which, if not met, could worsen their outcomes. These
influences are real and should be part of the pragmatic trial.
This challenge also raises the difficult question of whether therapies that the
patient would pay for outside of a trial should be paid for by them in the trial,
as the real world outcome could be influenced by the costs of the two
procedures available, regardless of the proved efficacy of each intervention.
Does physiotherapy airway clearance reduce acute
exacerbations in bronchiectasis?
Clinical trials of airway clearance are difficult to fully blind because of the
physical and complex nature of the intervention. It would be hard to define
exactly what the sham physiotherapy consists of and how to implement it if
was to be used as a placebo control. The trial would also be at a risk of
unblinding if patients who are familiar with the active airway clearance
intervention were allocated to the placebo arm. Physiotherapists would
probably be aware when implementing a sham procedure, further weakening
the blinding.
The results of such a fully blinded trial would be unlikely to translate into the
real world because biases surrounding clinician preference and co-intervention
bias are neglected. Even if patients were blinded, the physiotherapists may
not be confident in applying a sham procedure.
Similar problems would arise in a trial exploring a physiotherapy airway
clearance regime versus a drug because, even with outcome assessors
blinded, it raises additional issues with the practicality around the
communication between patients and clinicians. For example, scheduling
patient visits would be complex as patients could not be seen carrying trial
medications. A more pragmatic approach would be to blind external outcome
assessors or to use an objective primary outcome, such as number of
exacerbations, for the trial along with independent blinded adjudication of
outcomes (a blinded endpoint committee).
Methods that increase trial integrity
The prospective randomised open blinded endpoint evaluation
(PROBE) is an established method for trials.45-47 It emphasises
randomisation (with secure concealment until the allocation is
revealed) and blinded outcome assessment, two facets that
protect against bias. The blinding is implemented while
evaluating defined endpoints during a trial. Trials using PROBE
are regarded as open label with respect to patients and clinicians
but implement the blinding of outcome assessors or the blinded
evaluation of the trial’s endpoints. This approach of keeping
outcome assessors blind to the random allocation can be used
in most trials, including pragmatic effectiveness trials in which
outcomes are either subjective or objective. Blinding the
outcome assessors throughout a trial or using blinded evaluation
of endpoints by a committee at set points, reduces the effect of
observer and response bias, which can cause substantial reported
differences between treatments. Such methods would increase
rigour when double blinding of patients and clinicians is
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dropped, might be simpler to deliver, and can avoid the many
challenges we have outlined. For example, although the outcome
assessor is blinded, the study replicates routine practice in that
patients and clinicians know which intervention is being used
for a particular participant.
If blinded outcome assessment cannot be used in a trial, bias
can still be substantially reduced by using objective (eg, death)
rather than subjective (eg, quality of life) outcomes. This is
supported by a large meta-epidemiological study that found
little evidence of bias in unblinded trials that used objective
outcomes for both drug and non-drug interventions.48 Another
option to reduce bias is to modify the outcome to make it less
subjective. This can include avoiding surrogate markers and
limiting the size of any effect on a given clinical measure (eg,
using a 5 point Likert scale rather than 10 point Likert scale).49
Blinding in clinical trials can increase the reliability of a trial’s
results but has consequences for the practicality, safety, and
results of some trials. We suggest that the key elements for
clinical trials seeking to minimise bias when comparing the
effects of interventions should be adequate randomisation,
allocation concealment, use of objective outcomes, independent
blinded adjudication of outcomes, and, when possible, blinded
assessment of outcomes. The traditional double blinding of
participants and clinicians should not be regarded as a gold
standard to strive for and should be used only if the negative
effects are considered carefully and are outweighed by the
potential benefits.
Key messages
• Blinding of participants, clinicians, and others avoids bias in clinical
trials but can sometimes be detrimental to their integrity
• Some trials without blinding are inappropriately judged as poor quality
• Blinding participants and clinicians can affect recruitment, retention,
and applicability to routine practice as well as causing potential harm
to patients
• Double blinded designs are not always ideal for providing a reliable
answer to the trial’s research question
• People using such designs should rationalise their use of blinding
• A more nuanced approach, using blinded outcome assessment and
independent blinded adjudication of outcomes, alongside adequate
randomisation and objective outcome measures, should reduce the
main forms of bias
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